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Objectives: Carbapenem resistance mediated by mobile genetic elements has emerged worldwide and
has become a major public health threat. To gain insight into the molecular epidemiology of carbapenem
resistance in The Netherlands, Dutch medical microbiology laboratories are requested to submit sus-
pected carbapenemase-producing Enterobacterales (CPE) to the National Institute for Public Health and
the Environment as part of a national surveillance system.
Methods: Meropenem MICs and species identification were confirmed by E-test and MALDI-TOF and
carbapenemase production was assessed by the Carbapenem Inactivation Method. Of all submitted CPE,
one species/carbapenemase gene combination per person per year was subjected to next-generation
sequencing (NGS).
Results: In total, 1838 unique isolates were received between 2014 and 2018, of which 892 were unique
CPE isolates with NGS data available. The predominant CPE species were Klebsiella pneumoniae (n ¼ 388,
43%), Escherichia coli (n ¼ 264, 30%) and Enterobacter cloacae complex (n ¼ 116, 13%). Various carba-
penemase alleles of the same carbapenemase gene resulted in different susceptibilities to meropenem
and this effect varied between species. Analyses of NGS data showed variation of prevalence of carba-
penemase alleles over time with blaOXA-48 being predominant (38%, 336/892), followed by blaNDM-1 (16%,
145/892). For the first time in the Netherlands, blaOXA-181, blaOXA-232 and blaVIM-4 were detected. The
genetic background of K. pneumoniae and E. coli isolates was highly diverse.
Conclusions: The CPE population in the Netherlands is diverse, suggesting multiple introductions. The
predominant carbapenemase alleles are blaOXA-48 and blaNDM-1. There was a clear association between
species, carbapenemase allele and susceptibility to meropenem. K. van der Zwaluw, Clin Microbiol
Infect 2020;▪:1
© 2020 National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Published
by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Carbapenems are often used to treat patients infected with
bacteria that are resistant to cephalosporins, such as extended
spectrum b-lactamase-producing strains [1,2]. Resistance toal Institute for Public Health
ease Control Netherlands, PO
an der Zwaluw).
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y surveillance, Clinical Microcarbapenems is emerging worldwide and can be caused by
different mechanisms, such as porin loss, increased efflux pump
activity and carbapenemase production [3,4]. Carbapenemase-
producing Enterobacterales (CPE) are a threat to public health as
carbapenemase-encoding genes such as blaOXA-48, blaNDM and
blaKPC are predominantly located on plasmids, mobile elements
that can easily be exchanged between species, leading to rapid
spread of resistance [5]. Because different countries have found
significant variation in prevalence and distribution of
carbapenemase-encoding genes [6], the National Institute for
Public Health and the Environment (RIVM) has started surveillancehe Netherlands. Published by Elsevier Ltd on behalf of European Society of Clinical
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Netherlands [7]. In this study, we describe the molecular charac-
teristics of CPE isolates obtained within the national surveillance
system in the Netherlands between 2014 and 2018.
Materials and methods
Selection of bacterial isolates
For the national surveillance of CPE in The Netherlands, Dutch
medical microbiology laboratories are requested to submit human
Enterobacterales isolates with a reduced MIC for meropenem
(>0.25 mg/L) or imipenem (>1 mg/L) to the RIVM using an online
platform, Type-Ned. This low MIC threshold for submission was
chosen to monitor CPE rather than carbapenems-resistant Enter-
obacterales (CRE), because CPE represent a reservoir for the spread
of resistance genes. Of all submitted Enterobacterales isolates, only
the first unique species-gene combination per person per year was
included in this study. People from whom CPE were isolated are
referred to as ‘persons’, because they include both patients and
healthy individuals. Isolates from Dutch Caribbean territories were
excluded.
Confirmation, carbapenemase detection and PCR testing of bacterial
isolates
All submitted isolates were characterized using the following
methods: species identification was confirmed using matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF;
Bruker Daltonics GmbH, Bremen, Germany) and the MIC for mer-
openem of all isolates was confirmed by E-test (BioMerieux Inc.,
Marcy L’Etoile, France). Carbapenemase production was deter-
mined phenotypically by the Carbapenem Inactivation Method
(CIM) [8]. Carbapenemase-encoding genes were assessed by two
in-house developed multiplex PCR assays using primers targeting
the following genes (see Supplementary material, Table S1): KPC,
NDM, OXA-48-like, VIM, IMP [9], OXA-23-like, OXA-40-like, OXA-
51-like, OXA-58-like, OXA-134-like and the bacterial 16S rRNA gene
as an internal positive control [10]. PCR conditions were as
described previously [8].
Next-generation sequencing of bacterial isolates
Next-generation sequencing (NGS) was performed on all CPE
isolates included in this study, defined as being either CIM and/or
PCR-positive. Nucleic acid extraction was done using an in-house
protocol. Library preparation and sequencing of bacterial ge-
nomes were performed using the Illumina Nextera XT kit and the
HiSeq 2500 with a paired-end 100 cycles protocol. Nucleic acid
extraction and sequencing were performed by BaseClear (Leiden,
the Netherlands). Resulting 125 base reads were trimmed and deTable 1
Distribution of species among uniquea Dutch CPE isolates analysed by NGS, 2014e2018
2014 n (%) 2015 n (%)
No. of CPE with NGS 49 147
Klebsiella pneumoniae 21 (43) 75 (51)
Escherichia coli 14 (29) 34 (23)
Enterobacter cloacae complex 8 (16) 22 (15)
Citrobacter freundii 2 (4) 8 (5)
Klebsiella oxytoca 1 (2) 2 (1)
Proteus mirabilis 2 (4) 3 (2)
Other (15 species) 1 (2) 3 (2)
a One species/carbapenemase gene combination per person per year, excluding Dutch
b Isolates belonging to a known outbreak.
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formatics, Aarhus, Denmark). Samples that yielded over 200 con-
tigs with de novo assemblywere regarded as unreliable and omitted
from the study. In addition, we excluded contigs shorter than 500
bp or with an average read coverage below 30 from further ana-
lyses. To identify carbapenemase alleles and assess the presence of
other resistance genes, RESFINDER 2.1 [11] was used with an identi-
fication threshold of 90% and a minimum length of 60%. PCR results
were used to confirm RESFINDER data and discrepant tests were
repeated to rule out isolate mix-ups or contamination and to pre-
vent detecting truncated genes. For Klebsiella pneumoniae and
Escherichia coli isolates, multilocus sequence types (MLST) and
whole genome MLST (wgMLST) were extracted from NGS data
using SEQSPHERE 3.5.0 (Ridom GmbH, Münster, Germany). For MLST,
existing schemes were used [12,13]. For wgMLST, in-housewgMLST
schemes were designed. For the K. pneumoniae isolates, this
scheme comprised 4978 genes (3471 core-genome and 1507
accessory-genome targets) using K. pneumoniae MGH 78578
(NC_009648.1) as a reference genome. For the E. coli isolates, the in-
housewgMLST schemewas designed using E. coli strain CP000247.1
as a reference genome and included 4503 genes (3199 core-genome
and 1304 accessory-genome targets). Sequence reads were
deposited in the European Nucleotide Archive (ENA) under study
accession number PRJEB35685 (http://www.ebi.ac.uk/ena/data/
view/PRJEB35685).
Results
From 2014 until 2018, 1838 unique Enterobacterales isolates
suspected of carbapenemase production were submitted to the
RIVM. Of these, 892 (from 766 persons) were phenotypically
positive for carbapenemase activity and/or genotypically positive
for a carbapenemase-encoding gene and had reliable NGS data
available. For 303 persons (40%), an association with a stay
abroad was known (top countries: Turkey (n ¼ 63), Morocco
(n ¼ 47), India (n ¼ 26)). The annual number of CPE isolates
increased from 49 to 304 (Table 1), meanwhile the number of
participating laboratories increased from 40 to 51. During the
study period, there were three known outbreaks with CPE: an
outbreak in a hospital with 35 blaNDM-1-positive K. pneumoniae in
2015 [14], an outbreak in a nursing home with eight blaVIM-1-
positive E. coli in 2017 and one in a hospital with 23 blaNDM-5-
positive Citrobacter freundii in 2018.
Characteristics of bacterial isolates
Among the 892 CPE isolates, the predominant species were
K. pneumoniae (n¼ 388, 43%), E. coli (n¼ 264, 30%) and Enterobacter
cloacae complex (n ¼ 116, 13%) (Table 1). Overall, 275 (31%) were
phenotypically resistant for meropenem (EUCAST clinical break-
point, MIC >8 mg/L), 445 isolates (50%) were susceptible (MIC2016 n (%) 2017 n (%) 2018 n (%) Total n (%)
160 232 304 892 66b
73 (46) 98 (42) 121 (40) 388 (43) 35b
47 (29) 80 (34) 89 (29) 264 (30) 8b
16 (10) 32 (14) 38 (13) 116 (13)
4 (3) 9 (4) 33 (11) 56 (6) 23b
5 (3) 4 (2) 6 (2) 18 (2)
5 (3) 1 (0) 5 (2) 16 (2)
10 (6) 8 (3) 12 (5) 34 (4)
Caribbean territories.
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resistance levels. Sixty-four persons simultaneously carried two to
four distinct species with the same carbapenemase-encoding allele,
31 carried multiple species with different carbapenemase-
encoding alleles and eight carried multiple strains of the same
species with distinct carbapenemase-encoding alleles. Seven per-
sons persistently carried the same specieseallele combination over
a period of 2 or 3 years.Carbapenemase-encoding alleles
The most prevalent alleles found were blaOXA-48 (38%, 336/892)
and blaNDM-1 (16%, 145/892) (Fig. 1). In total, 26 different carbapen-
emase alleles were identified, including several alleles not reported
before in the Netherlands (see Supplementary material, Table S2). In
41 isolates, 34 of which belonged to Enterobacter cloacae complex, no
carbapenemase allele could be identified despite their phenotypic
carbapenemase activity as measured by CIM.
The alleles blaOXA-48 and blaNDM-1 were found across all species,
whereas >90% of blaKPC-3 and blaOXA-244 alleles were found in
K. pneumoniae and E. coli isolates, respectively. The blaOXA-23 allele
only occurred among Proteus mirabilis isolates.0%
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results of the 2014e2018 national laboratory surveillance, Clinical MicroThirty-five CPE isolates carried a blaNDM allele simultaneously
with another carbapenemase allele. The number of isolates with
multiple carbapenemase alleles increased over time from a single
isolate in 2014 to 20 in 2018.Association between carbapenemase allele and susceptibility to
meropenem
There was a marked association between susceptibility to
meropenem and the carbapenemase allele. Of all isolates carrying
blaOXA-48, only 18% (62/336) were resistant, whereas among isolates
with blaNDM-5 this proportion was 68% (62/91). Different alleles of
the same carbapenemase gene do not result in similar susceptibility
distributions either. For instance, of the isolates harbouring allele
blaNDM-1 only 31% (45/145) were resistant. Also, the relationship
between susceptibility to meropenem and the carbapenemase
allele is different between K. pneumoniae and E. coli isolates (Fig. 2).
Interestingly, 98% of K. pneumoniae carrying blaOXA-48 (168/172) or
blaNDM-1 (90/92) also carried an extended-spectrum b-lactamase.
For E. coli carrying blaOXA-48 or blaNDM-1, these values were 80% (77/
96) and 62% (16/26), respectively. The globally occurring extended-
spectrum b-lactamase gene blaCTX-M-15 [15] was found in 106/1728 2014 2015 2016 2017 2018
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K. pneumoniae carrying blaNDM-1, among E. coli carrying blaOXA-48 or
blaNDM-1, these values were 15% (14/96) and 19% (5/26) respectively.
An increasing number of isolates carried two carbapenemase
alleles. Of these, 30/35 isolates (86%) had a resistant phenotype of
which 29 had a MIC of 32 mg/L. Compared to isolates carrying a
single carbapenemase allele, isolates harbouring two carbapenem-
ase alleles were significantly more often resistant to meropenem
(p < 0.00001, Fisher's exact test).
Population diversity among K. pneumoniae and E. coli isolates
MLST inferred from the NGS data of 388 K. pneumoniae isolates
showed that the isolates belonged to 96 different classical MLST
sequence types (STs). The predominant STs were ST307 (n ¼ 47),
ST873 (n ¼ 37) and ST101 (n ¼ 35) accounting for 31% of all sub-
mitted carbapenemase-producing K. pneumoniae isolates. The in-
clusion of 35 isolates from an outbreak of NDM-1-producing ST873
K. pneumoniae in a Dutch hospital in 2015 caused the abundance of
ST873 isolates [14]. ST258, known for its worldwide presence [16],
was only found in 11 isolates (3%) in our selection. Among 264
E. coli isolates, there were 87 different classical MLSTs, top three
being ST38 (n ¼ 46), ST167 (n ¼ 22) and ST405 (n ¼ 16), accounting
for 32% of all E. coli isolates. ST131, known for its global occurrence
[17], was found eleven times, nine of which were isolated in 2017
(see Supplementary material, Table S3). The Simpson's index of
diversity for both the K. pneumoniae and E. coli selections based on
classical MLST was 0.948.
Whole genome MLST based on two schemes of 4978 and 4503
genes, respectively, resulted in the identification of 365 different
wgMLST profiles for K. pneumoniae and 264 for E. coli. A minimum
spanning tree based on these profiles showed a high degree of
genetic diversity within these populations with an average genetic
distance between neighbouring isolates of 730 genes for
K. pneumoniae and 771 genes for E. coli (Fig. 3). Plotting blaOXA-48
and blaNDM-1 on this minimum spanning tree showed that the
distribution of these carbapenemase alleles was not restricted to
isolates with related genetic background. In Fig. S1 (see Supple-
mentary material), classical MLST types have been indicated asFig. 3. Minimum spanning tree of Klebsiella pneumoniae (left) and Escherichia coli (right) ca
with colours.
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wgMLST with classical MLST.
Discussion
In the Netherlands, CPE isolates occur in many variations of both
carbapenemase alleles and genetic composition. Over the years
2014e2018, blaOXA-48 was the most predominant allele (40%), fol-
lowed by blaNDM-1 with 19%. Other European countries such as
France, also identified these alleles the most frequently [18,19].
During the study period, there were three known CPE outbreaks
(blaNDM-1-positive K. pneumoniae in 2015, blaVIM-1-positive E. coli in
2017 and blaNDM-5-positive C. freundii in 2018), which can be found
reflected in the results. Even so, there was still considerable vari-
ation in carbapenemase allele distribution among CPE species
collected in the Netherlands, indicating that the CPE population in
the Netherlands is dynamic. Also, wgMLST showed the
K. pneumoniae and E. coli CPE populations were highly diverse.
Especially the increasing occurrence of CPE isolates harbouring two
distinct carbapenemase alleles combined with the observed higher
level of resistance to meropenem among these isolates, may
represent an emerging threat.
We identified numerous alleles of carbapenemase-encoding
genes that to our knowledge have not been reported in the
Netherlands before. Some of these alleles were only found once, but
others such as blaOXA-181 were increasingly found after their first
detection. The predominant classical MLST type among blaOXA-181-
carrying K. pneumoniae and E. coli isolates were ST147 and ST410,
respectively. These sequence types are known to circulate around the
world [20,21], whichmight be reflected by the increasing occurrence
of blaOXA-181 in the Netherlands. Another carbapenemase allele
worth noting is blaVIM-1, which until 2016 was found rarely among
Enterobacterales in the Netherlands and globally [22], but was found
25 times in 2017, 11 of which belonged to an outbreak.
Isolates with different carbapenemase alleles had different mer-
openem susceptibility levels, indicating that each allele does not
result in the same resistance phenotype. Differences in the level of
expressionof the carbapenemasesor theiraffinity formeropenemare
most likely responsible for this phenomenon [23,24]. The effect of therbapenemase-producing Enterobacterales isolates with blaOXA-48 and blaNDM-1 indicated
ics of carbapenemase-producing Enterobacterales in the Netherlands;
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between K. pneumoniae and E. coli isolates. This may be caused by
other factors influencing the susceptibility such as porin loss or efflux
pumps [25] or the presence of extended-spectrum b-lactamases,
which may be more common and/or more efficient among
K. pneumoniae than among E. coli isolates [26]. Some carbapenemase
alleles are primarily found among certain species, which is in
concordance with previous findings showing that some of the plas-
mids onwhich these alleles are locatedhave anarrowhost range [27].
Unfortunately, the NGS data available were based on short-read
sequencing, making them unsuitable to infer conclusions on
plasmid content or whether resistance genes are chromosomally
located or not. This is a limitation of this study.
The occurrence of CIM-positive isolates for which no
carbapenemase-encoding gene was identified, might be explained
by either false-positivity of the CIM, or presence of a currently
unknown carbapenemase-encoding gene. The fact that these were
primarily Enterobacter cloacae complex might suggest false posi-
tivity due to overexpressed AmpC [28,29]; however, among these
isolates, 37% (15/41) carried an acquired AmpC gene, not more
frequently compared with overall (37%, 326/892). Other mutations
or differences in permeability may play a role in their CIM posi-
tivity. In addition, these isolates could be tested for carbapenemase
activity with a different test such as MALDI-TOF mass spectrometry
meropenem-hydrolysis assay [30].
The majority of the CPE isolates (69%) had MICs below the
clinical breakpoint for resistance, underlining the distinction be-
tween CPE and CRE. Even though CRE might be considered more
clinically relevant than CPE, the latter represent a reservoir for
spread of resistance genes. To monitor these isolates, our surveil-
lance system uses the low threshold (MIC >0.25 mg/L for mer-
openem) for submission of isolates. For the national
carbapenemase surveillance, we only performed susceptibility
testing with meropenem to confirm this threshold. The lack of data
on susceptibility of other carbapenems and other antibiotics is
another limitation of this study.
Between 2014 and 2018, the number of submitted CPE isolates
increased each year. Whether this increase reflects the increased
commitment of medical microbiology laboratories to submit sam-
ples or is also an actual increase of the occurrence of CPE in the
Netherlands is unknown, because the surveillance system in the
Netherlands is based on voluntary submission of isolates, which is a
third limitation of this study. The implementation of Type-Ned in
2016, where medical microbiology laboratories can register an
isolate online, monitor its progress and view results and basic
statistics, may have contributed to an increased willingness to
submit isolates. In addition, if the occurrence of CPE has indeed
increased in the Netherlands, it has not caused an increased pro-
portion of E. coli and K. pneumoniae isolates with elevated carba-
penem MIC values (https://www.rivm.nl/bibliotheek/rapporten/
2019-0038.pdf).
Of the 766 persons included in this study, 303 (40%) had a
known association with a stay abroad. However, such additional
informationwas only available for 551 persons, resulting in a higher
percentage (55%).
In conclusion, during the study period 2014e2018 the number
of isolates submitted for the national CPE surveillance increased
each year and themajority of the CPE isolates harbour either blaOXA-
48 or blaNDM-1 and belong to the species K. pneumoniae and E. coli.
However, we observed an increasing number of CPE isolates with
other or multiple carbapenemase alleles. Also, we noticed varia-
tions in susceptibility to meropenem between different carbapen-
emase alleles and species. The prevalence of the carbapenemase
alleles varied over time and the genetic backgrounds of both the
K. pneumoniae and E. coli isolates were highly diverse, suggestingPlease cite this article as: van der Zwaluw K et al., Molecular characterist
results of the 2014e2018 national laboratory surveillance, Clinical Micromultiple introductions of CPE in the Netherlands. This dynamic CPE
population in the Netherlands justifies a continued close moni-
toring using extensive surveillance as described here.
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